Delving into the Latest Updates on KYS202004A with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

KYS202004A

Target

IL-17A x TNF-α

Mechanism

IL-17A inhibitors(Interleukin 17A inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Psoriasis

Inactive Indication-

Originator Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价在健康成年受试者中单次注射不同剂量KYS202004A注射液后的安全性和耐受性。次要目的：评价在健康成年受试者中单次注射不同剂量KYS202004A注射液后的药代动力学（PK）特征。评价在健康成年受试者中单次注射不同剂量KYS202004A注射液后的免疫原性的情况。探索性目的：探索在健康成年受试者中单次注射不同剂量KYS202004A注射液后生物标志物变化。

[Translation]

Primary objective: To evaluate the safety and tolerability of KYS202004A injection after a single injection of different doses in healthy adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of KYS202004A injection after a single injection of different doses in healthy adult subjects. To evaluate the immunogenicity of KYS202004A injection after a single injection of different doses in healthy adult subjects. Exploratory objective: To explore the changes in biomarkers after a single injection of different doses of KYS202004A injection in healthy adult subjects.

Start Date-

Sponsor / Collaborator